Grand Hyatt New York
109 E 42nd Street New York, NY 10017
It is becoming increasingly difficult to identify and attract novel and potentially profitable products from among the usual suspects of Cardiovascular, Oncology, Immunology and CNS. The “low-hanging fruit” in these therapeutic fields has been largely plucked, and competition for the other assets is fierce.
- So where should companies be looking next?
- Which fields have the potential to provide big wins on the back of intelligent bets?
- And how do you measure and compensate the executives placing these bets?
- Will new technologies be the drivers of commercial success, or can creative marketing strategies continue to create blockbusters from incremental improvements in treatment?
- Will the deep cuts in-house R&D being made by the largest companies be accompanied by an improvement in productivity, or will partnering become even more critical to success?
- Will investment in new therapeutic areas result in products with sufficient revenues to drive earnings growth?
The 9th Annual Pharmaceutical Strategic Outlook (PSO) conference is an in-depth analysis on the top issues affecting the industry, creating a dynamic three days of networking and discussion. The conference offers a personal and interactive setting with in-depth on-stage interviews, panels, one-on-one partnering meetings and company presentations by carefully selected biotech companies.
Senior level business development and licensing executives from small to large pharmaceutical and biotechnology companies attend PSO to meet their current and potential strategic partners as well as hear from industry stakeholders and key thought leaders who’ll share practical advice and strategies on how to structure successful deals.
PSO 2012 will include thought-provoking discussions of the strategies employed by companies who have defied conventional wisdom to place obscure bets. And won.
For more information, click here.